Known as "the first stock of the Ginkgo industry", Baikang Biological Group Holdings Ltd (Baikang Biological) has filed a prospectus 1 (F-1/A) with the U.S. Securities and Exchange Commission (SEC) on July 30, US time, and the company intends to list on the NASDAQ market under the ticker code "BKSW." Joseph Stone Capital, LLC underwriter of the IPO. The IPO of Baikang Biological plans to issue 1.6 million to 2.4 million common shares, with a maximum offering price of no more than $6 per share, and a net offering of $6.4 million to $10.2 million.
As a provider of a variety of proprietary natural health and nutrition products specializing in ginkgo, Baikang Biological has established five core product lines, including 26 products in total including nutritional health products (including ginkgo powder drinks and various dietary supplements). It is reported that if the "beach landing" success, marking China's nutritional health food industry to a new level.
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
